Glucocorticoid treatment in rheumatoid arthritis

Bibliography

• Pincus T, Callahan LF, Sale WG, et al. Severe functional decline, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72
   PubMed Web of Science ®Google Scholar
• Gotzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998;316:811-18
   PubMedGoogle Scholar
• Saag KG, Criswell LA, Sems KM, et al. Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996;39:1818-25
   PubMed Web of Science ®Google Scholar
• Hench P. Effects of cortisone in the rheumatic diseases. Lancet 1950;2:483-4
   Google Scholar
• Saag KG. Resolved: low-dose glucocorticosteroids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Rheum 2001;45:468-71
   PubMed Web of Science ®Google Scholar
• Conn DL. Resolved: low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 2001;45:462-7
   Google Scholar
• Russell AS. Oral corticosteroids should not be used in rheumatoid arthritis. Rheumatologist 2013;7:29-30
   Google Scholar
• Kirwan JR. What about prednisone? Rheumatologist 2013;7:18
   Google Scholar
• Thiele K, Buttgereit F, Huscher D, et al. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Care Res 2005;53:740-7
   Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum 2014;73(3):492-509
   PubMed Web of Science ®Google Scholar
• Empire Rheumatism Council: multi-center controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis: results up to one year. Ann Rheum Dis 1955;14:353-70
   PubMed Web of Science ®Google Scholar
• Joint Committee of the Medical Research Council and Nuffield Foundation: a comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959;18:173-88
   PubMed Web of Science ®Google Scholar
• Harris ED Jr, Emkey RD, Nichols JE, et al. low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983;10:713-21
   PubMed Web of Science ®Google Scholar
• Kirwan JR. The Arthritis and Rheumatism Council and Low Dose Glucocorticoid Study Group: the effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:1442-6
   Google Scholar
• Van Everdingen AA, Jacobs JWG, Van Reesema DR, Bijlsma JWJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 2002;136:1-12
   PubMed Web of Science ®Google Scholar
• Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. Br J Rheumatol 1998;37:930-6
   PubMedGoogle Scholar
• Svensson B, Boonen A, Albertsson K, et al. for the BARFOT Study Group. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360-70
   PubMed Web of Science ®Google Scholar
• Wassenberg S, Rau R, Steinfeld P, Zeidler H; for the Low-Dose Prednisolone Therapy Study Group. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicentre, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80
   PubMed Web of Science ®Google Scholar
• Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double blind parallel study of 174 patients. Br J Rheumatol 1997;36:345-52
   PubMedGoogle Scholar
• Rau R, Wassenberg S, Herborn G, et al. A new method of scoring radiographic change in rheumatoid arthritis. J Rheumatol 1998;25:2094-107
   PubMed Web of Science ®Google Scholar
• Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomized controlled trial. Ann Rheum Dis 2004;63:797-803
   PubMed Web of Science ®Google Scholar
• Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18
   PubMed Web of Science ®Google Scholar
• Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: longterm structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56
   PubMed Web of Science ®Google Scholar
• Choy EHS, Smith CM, Farewell V, et al. for the CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arthritis) Trial Group. Factorial randomized controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008;67:656-63
   PubMed Web of Science ®Google Scholar
• Hansen M, Podenphant J, Florescu A, et al. A randomized trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis 1999;58:713-18
   PubMed Web of Science ®Google Scholar
• Todoerti M, Sciré CA, Boffini N, et al. Early disease control by low-dose prednisone co-medication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Aced Sci 2010;1193:139-45
   Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet 2004;364:263-9
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion into a MTX-based tight control strategy for early rheumatoid arthritis: better control of disease and erosive joint damage. Results from the double-blind randomized CAMERA-II trial. Ann Rheum Dis 2011;70(Suppl 3):114
   Google Scholar
• Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomized controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005;64:1288-93
   PubMed Web of Science ®Google Scholar
• Van Gestel AM, Laan RFJM, Haagsma CJ, et al. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Brit J Rheumatol 1995;34:347-51
   PubMedGoogle Scholar
• Pincus T. The clinical efficacy of 3 mg/day prednisone in patients with rheumatoid arthritis: evidence from a randomized, double-blind, placebo-controlled withdrawal clinical trial. Clin Exp Rheumatol 2011;29(Suppl 68):S73-6
   Google Scholar
• Hollander JL. Intrasynovial corticoid therapy. In: Hollander JL, editor. Arthritis & allied conditions. 7th edition. Lea & Febiger, Philadelphia; 1966
   Google Scholar
• Mc Carty DJ, Harman JG, Grassanovich JL, et al. Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone hexacetonide. J Rheumatol 1995;22:1631-5
   Google Scholar
• Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008;67:815-22
   PubMed Web of Science ®Google Scholar
• Van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69:1913-19
   PubMed Web of Science ®Google Scholar
• Del Rincon I, Battaforano DF, Restrepo JF, et al. A glucocorticoid dose threshold associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2014;66:264-72
   PubMed Web of Science ®Google Scholar
• Mazzantini M, Talarico R, Doveri M, et al. Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. J Rheumatol 2010;37:2232-6
   PubMed Web of Science ®Google Scholar
• Van der Goes MC, Jacobs JWG, Bijlsma JWJ. Toward safer treatment with glucocorticoids: via patient and rheumatologist perspectives to recommendations on monitoring for adverse events. Clin Exp Rheumatol 2011;29(Suppl 68):S116-20
   Google Scholar
• Hoes JN, Jacobs WG, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702
   PubMed Web of Science ®Google Scholar
• Reckart MD, Eisendraht SJ. Exogenous corticosteroid effects on mood and cognition: case presentations. Int J Psychosom 1990;37:57-61
   PubMedGoogle Scholar
• Stein CM, Pincus T. Clinical pharmacology for rheumatic diseases. Glucocorticoids. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 5th edition. Saunders, Philadelphia; 1997
   Google Scholar
• Goekopp-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study): a randomised controlled trial. Arthritis Rheum 2005;52:3381-90
   PubMedGoogle Scholar
• Van Tuyl LH, Plass AM, Lems WF, et al. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007;66:974-6
   PubMed Web of Science ®Google Scholar
• Laan RF, Van Riel PL, Van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-8
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000
   PubMed Web of Science ®Google Scholar
• Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40
   PubMed Web of Science ®Google Scholar
• Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-9
   PubMedGoogle Scholar
• Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31
   PubMed Web of Science ®Google Scholar
• Poon M, Gertz SD, Fallon JT, et al. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis 2001;155:371-80
   PubMedGoogle Scholar
• Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94
   PubMed Web of Science ®Google Scholar
• Cobb S, Aanderson F, Bauer W. Length of life and causes of death in rheumatoid arthritis. N Engl J Med 1953;249:553-6
   PubMed Web of Science ®Google Scholar
• Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2013. [ Epub ahead of print]
   Google Scholar
• Scott DL, Coulton BL, Chapman JH, et al. The long-term effects of treating rheumatoid arthritis. J R Coll Physicians Lond 1983;17:79-85
   PubMedGoogle Scholar
• Corbet M, Dalton S, Young A, et al. Factors predicting, death, survival, and functional outcome in a prospective study of early rheumatoid disease over 15 years. Br J Rheumatol 1993;32:481-4
   Google Scholar
• Singh G, Fries JF, Williams CA, et al. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Hickley SH, Hallgren R, et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:1415-21
   Google Scholar
• Livanou T, Ferriman D, James VHT. Recovery of hypothalamo-pituitary adrenal function after corticosteroid therapy. Lancet 1967;2:857
   Google Scholar
• Hafstrom I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction after 4 years: An open 2 year continuation study. Ann Rheum Dis 2009;68:508-13
   PubMed Web of Science ®Google Scholar
• Kirvan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007(1):CD006356
   Google Scholar
• Mc Dougall R, Sibley J, Haga M, et al. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994;21:1207-13
   PubMedGoogle Scholar
• DaSilva JAP, Jacobs JWG, Kirwan JR, et al. Safety of glucocorticoid treatment in rheumatoid arthritis published evidence and prospective trial data. Ann Rheum Dis 2006;5:285-93
   Google Scholar
• Caplan L, Russell AS, Wolfe F, et al. Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol 2005;32:1862-5
   Google Scholar